Correlation of the detection rate of upper GI cancer with artificial intelligence score: results from a multicenter trial (with video)

Yan-Dong Li,Hui-Zhang Li,Sheng-Sen Chen,Chao-Hui Jin,Ming Chen,Ming Cheng,Min-Jun Ma,Xiao-Ping Zhang,Xin Wang,Jian-Bo Zhou,Ming-Tong Chen,Jiang-Ning Chen,Shan Yu,Tie-Jun Wang,Wei-Ping Fang,Xian-Wei Cao,Xiao-Jie Yu,Ling-Bin Du,Shi Wang
DOI: https://doi.org/10.1016/j.gie.2021.12.019
IF: 10.396
2021-12-01
Gastrointestinal Endoscopy
Abstract:BACKGROUND AND AIMS: The quality of EGD is a prerequisite for a high detection rate of upper GI lesions, especially early gastric cancer. Our previous study showed that an artificial intelligence system, named intelligent detection endoscopic assistant (IDEA), could help to monitor blind spots and provide an operation score during EGD. Here, we verified the effectiveness of IDEA to help evaluate the quality of EGD in a large-scale multicenter trial.METHODS: Patients undergoing EGD in 12 hospitals were consecutively enrolled. All hospitals were equipped with IDEA developed using deep convolutional neural networks and long short-term memory. Patients were examined by EGD, and the results were recorded by IDEA. The primary outcome was the detection rate of upper GI cancer. Secondary outcomes were part scores, total scores, and endoscopic procedure time, which were analyzed by IDEA.RESULTS: A total of 17,787 patients were recruited. The total detection rate of cancer-positive cases was 1.50%, ranging from .60% to 3.94% in each hospital. The total detection rate of early cancer-positive cases was .36%, ranging from .00% to 1.58% in each hospital. The average total score analyzed by IDEA ranged from 64.87 ± 16.87 to 83.50 ± 9.57 in each hospital. The cancer detection rate in each hospital was positively correlated with total score (r = .775, P = .003). Similarly, the early cancer detection rate was positively correlated with total score (r = .756, P = .004).CONCLUSIONS: This multicenter trial confirmed that the quality of the EGD result is positively correlated with the detection rate of cancer, which can be monitored by IDEA. (Clinical trial registration number: ChiCTR2000029001.).
gastroenterology & hepatology
What problem does this paper attempt to address?